Gilead

Galapagos and Gilead have forged a collaborative partnership, with complementary strengths, a passion for innovation and a shared vision of transforming the treatment of fibrotic and inflammatory diseases for patients.

Through our innovative partnership we are developing a deep pipeline of investigational molecules with novel mechanisms of action to bring meaningful improvements to the lives of patients.

At ERS this year, we hosted two symposia as well as a number of ‘Meet the Expert' and lunchtime sessions. Find out more about our two symposia by following the links below.
Close X

Time for change? Pioneering in IPF management

At the ERS, our expert faculty discussed the future of idiopathic pulmonary fibrosis (IPF) and how we can work towards the best possible patient care. We considered cutting-edge techniques and functional tests that can aid diagnosis and management, and discussed the landmark ISABELA studies where some of these approaches are being pioneered.

The symposium took place on:
Monday 7 September at 13:15-14:15pm CET.

To access the full symposium you must be a healthcare professional registered to ERS 2020 virtual congress.

Watch now

Agenda

Time for change? Pioneering in IPF management
5 minutes
Time for change
Toby Maher, Keck School of Medicine, University of Southern California, Los Angeles, CA, USA
15 minutes
Functional respiratory imaging: a novel imaging modality for IPF
Paul Ford, Galapagos, UK
Muhunthan Thillai, Cambridge Interstitial Lung Disease Unit, Royal Papworth Hospital, Cambridge, UK
15 minutes
Maintaining the momentum: ensuring optimal management of patients with IPF
Lisa Lancaster, Vanderbilt University Medical Center, Nashville, TN, USA
15 minutes
ISABELA: A landmark study in IPF
Toby Maher, USA
10 minutes
Live Q&A and closing remarks
All speakers, facilitated by Toby Maher, USA

Faculty Bios

Toby Maher
University of Southern California, Los Angeles, CA
Toby Maher is Professor of Medicine and Director of Interstitial Lung Disease at Keck School of Medicine, University of Southern California, Los Angeles. His research interests include clinical trials, biomarker discovery, the lung microbiome and host immune response in the pathogenesis of IPF and clinical trials in fibrotic lung disease. He is an associate Editor for American Journal of Respiratory and Critical Care Medicine. He has authored over 260 papers and book chapters on IPF.
Paul Ford
Galapagos
Dr. Paul Ford is Head of Respiratory Medicine at Galapagos where his primary responsibility lies with the IPF franchise, in particular the inception and oversight of the ISABELA studies.
Lisa Lancaster
Vanderbilt University Medical Center, Nashville, TN
Dr. Lisa Lancaster has extensive experience with clinical management and research in IPF. She serves as Director of the Interstitial Lung Disease Program and a Medical Advisor for the pulmonary rehabilitation program at Vanderbilt University Medical Center (VUMC) in Nashville. Dr. Lancaster established the first VUMC IPF/ILD clinic and support group and has been recognized for excellence in patient care.
Muhunthan Thillai
Royal Papworth Hospital, UK
Dr. Muhunthan Thillai is the Lead Clinician for the Cambridge Interstitial Lung Disease Unit. He has been awarded a number of clinical and research prizes from societies including the Eastern Thoracic Society, Imperial College London and the National Heart and Lung Institute.
Close X

Improving pulmonary fibrosis diagnosis and care 
in Europe

In partnership with EU-IPFF, the European Idiopathic Pulmonary Fibrosis and Related Disorders Federation, we reviewed topics such as insights into the patient journey and key unmet needs, as well as discussed access to IPF care across Europe. Additionally, a new educational program for general practitioners on pulmonary fibrosis identification was presented.

The symposium took place on:
Wednesday 9 September at 13:15-14:15pm CET.

To access the full symposium you must be a healthcare professional registered to ERS 2020 virtual congress.

Watch now

Agenda

Improving pulmonary fibrosis diagnosis and care 
in Europe
5 minutes
Welcome
Liam Galvin, EU-IPFF Secretary and Director of Irish Lung Fibrosis Association, Ireland
15 minutes
The path to diagnosis in Europe: results of the EU-IPFF/Galapagos patient survey
Steve Jones, EU-IPFF President and Action for Pulmonary Fibrosis Chair, UK
Marlies Wijsenbeek, Erasmus Medical Centre, Rotterdam, The Netherlands
15 minutes
EU-IPFF Benchmarking Report: IPF care across Europe
Francesco Bonella, University of Duisberg-Essen, Germany
Jean-Michel Fourrier, EU-IPFF Board Member and Association Pierre Enjalran Fibrose Pulmonaire Idiopathique President, France
10 minutes
Educating general practitioners about pulmonary fibrosis: the Royal College of General Practitioners (RCGP) e-learning course
Helen Parfrey, Royal Papworth Hospital, Cambridge, UK
10 minutes
Live Q&A
5 minutes
Conclusion and thanks
Steve Jones, UK

About EU-IPFF

The European Idiopathic Pulmonary Fibrosis and Related Disorders Federation (EU-IPFF) is a non-profit organization that brings together European national patient associations committed to defending their vision of equal access to treatment and care for all patients with IPF, regardless of geography, socio-economic status or age. The EU-IPFF aim to serve as a trusted resource for the IPF community by raising awareness, providing disease education, advancing care, and supporting research for IPF whilst defending the interests of patients with IPF at the European level (information provided from https://www.eu-ipff.org/ and approved by the EU-IPFF).

Sign up for updates from Galapagos and Gilead